Generate Biomedicines is trading at $19.80, up 11.71%, primarily on biotech-sector momentum.
- The stock rose 9.93% on August 24, 2026, marking its second consecutive strong advance.
- No new company-specific announcement was identified for August 25; the latest update was its August 6 second-quarter report.
- Biotech ETF XBI is up 2.06% amid a broader risk-on tone, with no confirmed Generate-specific catalyst.